Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment.

abstract：OBJECTIVE:To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer's disease. Patients had a mean age of 74 years, a mean disease...

journal_title：PharmacoEconomics

authors： Green C,Picot J,Loveman E,Takeda A,Kirby J,Clegg A

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVE:To evaluate the effect of using different cost-effectiveness measures in the economic evaluation of cholesterol-modifying pharmacotherapy. DESIGN AND SETTING:An economic model was used to examine the extent to which the relative cost effectiveness of cholesterol-modifying agents varies depending upon the cos...

journal_title：PharmacoEconomics

authors： Morris S,Godber E

更新日期：1999-08-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the in...

journal_title：PharmacoEconomics

authors： Fust K,Li X,Maschio M,Villa G,Parthan A,Barron R,Weinstein MC,Somers L,Hoefkens C,Lyman GH

更新日期：2017-04-01 00:00:00

abstract：:Whereas individual cost-effectiveness analyses of new agents for acute leukaemia should be performed in target populations, any meaningful pharmacoeconomic evaluation of treatment options for this condition should include the many types of costs and outcomes in unselected, representative groups of patients. Both direc...

journal_title：PharmacoEconomics

authors： Jønsson V,Hansen MM,Ljungman P,Kaasa S

更新日期：1999-02-01 00:00:00

abstract：:The National Institute for Health and Care Excellence (NICE) is only one of several organisations internationally that uses economic evaluation as part of decision making regarding funding and pricing of new medical technologies. However, it can be argued that NICE has developed a more prominent international profile ...

journal_title：PharmacoEconomics

authors： Sculpher M,Palmer S

更新日期：2020-03-01 00:00:00

abstract：:In an effort to control escalating health expenditures, especially in hospitals, many countries are planning or experimenting with prospective budgeting systems. Belgium is no exception and has recently introduced, with some success, limited fixed charges per hospital admission and/or per hospitalisation day for labor...

journal_title：PharmacoEconomics

authors： Closon MC,Crott R,Even-Adin D

更新日期：1996-03-01 00:00:00

abstract：:Pharmacoeconomic data may be obtained within the context of randomised clinical trials (RCTs) and from effectiveness studies in the 'real world'. The differences between the 2 types of study design have implications for the types of data that can be obtained and the interpretation of the resulting findings. Because RC...

journal_title：PharmacoEconomics

authors： Revicki DA,Frank L

更新日期：1999-05-01 00:00:00

abstract：:In an attempt to obtain an appropriate estimate of the excess costs of production losses arising from morbidity in patients with diabetes, we compared the number of sick days and permanently disabled individuals in a diabetic population and the corresponding general population. These comparisons show that the rate of ...

journal_title：PharmacoEconomics

authors： Persson U

更新日期：1995-01-01 00:00:00

abstract：BACKGROUND:Invasive fungal infections in neutropenic patients treated for haematological malignancies are associated with a high mortality rate and, therefore, require early treatment. As the diagnosis of invasive fungal infections is difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has bee...

journal_title：PharmacoEconomics

authors： de Vries R,Daenen S,Tolley K,Glasmacher A,Prentice A,Howells S,Christopherson H,de Jong-van den Berg LT,Postma MJ

更新日期：2008-01-01 00:00:00

abstract：:Pharmacoeconomics identifies, measures, and compares the costs and consequences of pharmaceutical products and services. The cost effectiveness of a pharmacotherapy in a particular indication depends on the molecular configuration of the drug, its safety and efficacy, and local market factors such as the acquisition ...

journal_title：PharmacoEconomics

authors： Milne RJ

更新日期：1994-10-01 00:00:00

abstract：BACKGROUND:Lung cancer is among the top causes of cancer-related deaths. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free survival compared with standard chemotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). OBJECTIVE:The aim o...

journal_title：PharmacoEconomics

authors： Schremser K,Rogowski WH,Adler-Reichel S,Tufman AL,Huber RM,Stollenwerk B

更新日期：2015-11-01 00:00:00

abstract：:Studies have not previously reported the indirect cost burden of multiple sclerosis (MS) from an employer perspective. To compare annual indirect costs between privately insured US employees with MS and matched employee controls. A retrospective analysis of a privately insured claims database containing disability dat...

journal_title：PharmacoEconomics

authors： Ivanova JI,Birnbaum HG,Samuels S,Davis M,Phillips AL,Meletiche D

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Economic models are considered to be important, as they help evaluate the long-term impact of diabetes treatment. To date, it appears that no article has reviewed and critically appraised the cost-effectiveness models developed to evaluate new oral treatments [glucagon-like peptide-1 (GLP-1) receptor agonist...

journal_title：PharmacoEconomics

authors： Asche CV,Hippler SE,Eurich DT

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Schizophrenia is a devastating and costly illness that affects 1% of the population in the US. Effective pharmacological therapies are available but suboptimal patient adherence to either acute or long-term therapeutic regimens reduces their effectiveness. The availability of a long-acting injection (LAI) fo...

journal_title：PharmacoEconomics

authors： Edwards NC,Rupnow MF,Pashos CL,Botteman MF,Diamond RJ

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVE:The study aimed to conduct a systematic literature search to identify health state utilities for weight change in type 2 diabetes mellitus (T2DM) and to review those values for appropriateness for inclusion in a submission to the National Institute for Health and Clinical Excellence (NICE). METHODS:The searc...

journal_title：PharmacoEconomics

authors： Doyle S,Lloyd A,Moore L,Ray J,Gray A

更新日期：2012-12-01 00:00:00

abstract：BACKGROUND:The English community pharmacy New Medicine Service (NMS) significantly increases patient adherence to medicines, compared with normal practice. We examined the cost effectiveness of NMS compared with normal practice by combining adherence improvement and intervention costs with the effect of increased adher...

journal_title：PharmacoEconomics

authors： Elliott RA,Tanajewski L,Gkountouras G,Avery AJ,Barber N,Mehta R,Boyd MJ,Latif A,Chuter A,Waring J

更新日期：2017-12-01 00:00:00

abstract：:The objective of this study was to demonstrate the cost effectiveness of long term maintenance treatment with citalopram versus standard therapy (defined as short term antidepressant treatment) in patients with major depression in Germany. We chose doxepin, amitriptyline and trimipramine as standard therapy because th...

journal_title：PharmacoEconomics

authors： Nuijten MJ,Hardens M,Souêtre E

更新日期：1995-08-01 00:00:00

abstract：:Health economic models for identifying therapeutic options that maximise health benefits from limited healthcare resources are being developed in a number of therapeutic areas. The development of such a model for upper gastrointestinal (UGI) symptoms to support decision-making by primary care clinicians is of particul...

journal_title：PharmacoEconomics

authors： Haycox A,Butterworth M,Walley T,Barton S

更新日期：1998-01-01 00:00:00

abstract：:Fluconazole (FLU) is an alternative to amphotericin B (AMB) for the treatment of candidemia in non-neutropenic patients. This agent has similar clinical efficacy but significantly reduced adverse effects compared with AMB. Using the database from a Canadian randomised multicentre comparative trial of FLU versus AMB in...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Phillips P,Rotstein C,Puodziunas A,Shafran S,Garber G,Smaill F,Salit I,Miller M,Williams K,Conly J,Singer J,Ioannou S

更新日期：1998-05-01 00:00:00

abstract：BACKGROUND:In the past decade, the range of contraceptives available has increased dramatically. There are limited data on the factors that determine women's choices on contraceptive alternatives or what factors providers consider most important when recommending contraceptive products to women. OBJECTIVES:Our objecti...

journal_title：PharmacoEconomics

authors： Knox SA,Viney RC,Street DJ,Haas MR,Fiebig DG,Weisberg E,Bateson D

更新日期：2012-12-01 00:00:00

abstract：:As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the othe...

journal_title：PharmacoEconomics

authors： Tse G,Thompson D,Procyshyn RM

更新日期：2003-01-01 00:00:00

abstract：:Epilepsy is a chronic condition with numerous social and psychological consequences. This work aimed to review available data on epilepsy and the impact of surgical and pharmaceutical treatments on the quality of life in adults and children. Research on quality of life in epilepsy is characterised by a wide and fragme...

journal_title：PharmacoEconomics

authors： Berto P

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:A wide variety of oral antiplatelet trials have been carried out, and a large number of cost-effectiveness estimates based on them have been published. OBJECTIVE:To assess the cost effectiveness of oral antiplatelet treatments in the prevention of cardiovascular events. METHODS:A comprehensive literature s...

journal_title：PharmacoEconomics

authors： Heeg B,Damen J,Van Hout B

更新日期：2007-01-01 00:00:00

abstract：:Using the method of willingness to pay (WTP), this study assesses the value of a new antidepressant, moclobemide, relative to that of tricyclic antidepressants (TCAs), which have equivalent efficacy but less favourable adverse effect profiles. From a published meta-analysis of controlled clinical trials, we identified...

journal_title：PharmacoEconomics

authors： O'Brien BJ,Novosel S,Torrance G,Streiner D

更新日期：1995-07-01 00:00:00

abstract：:Recent studies have shown that ACE inhibitors reduce morbidity and mortality after myocardial infarction (MI). While these trials have obvious clinical implications, the widespread introduction of a new treatment for a condition as common as MI also has clear cost implications. The results of the post-MI studies with ...

journal_title：PharmacoEconomics

authors： Hummel S,Piercy J,Wright R,Davie A,Bagust A,McMurray J

更新日期：1997-08-01 00:00:00

abstract：:The pharmacoeconomics of the low molecular weight heparin (LMWH) enoxaparin in the prophylaxis and treatment of venous thromboembolism have mostly been investigated in cost-effectiveness studies that estimated direct costs associated with treatment, using decision analyses and clinical outcome data from randomised con...

journal_title：PharmacoEconomics

authors： Bergqvist D

更新日期：2002-01-01 00:00:00

abstract：:Uncertainty in the decision-making process for reimbursement of health technologies could be reduced if additional information were available. Although methods to evaluate the monetary value of the uncertainty have been previously described, an economic evaluation of alternative methods to acquire additional informati...

journal_title：PharmacoEconomics

authors： Shavit O,Leshno M,Goldberger A,Shmueli A,Hoffman A

更新日期：2007-01-01 00:00:00

abstract：:Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy in patients with LGS uncontrolled on one to t...

journal_title：PharmacoEconomics

authors： McCormack PL

更新日期：2012-03-01 00:00:00

abstract：:Health reform is currently the predominant health policy issue in the US. It carries profound implications for the pharmaceutical field, including the possibility of price controls that could stifle pharmaceutical research. While policy makers are contemplating alternative approaches to reform, the marketplace for pha...

journal_title：PharmacoEconomics

authors： Meyer PR

更新日期：1994-01-01 00:00:00

abstract：:In this review, the economic aspects of pneumococcal pneumonia are analysed, including the costs, cost effectiveness and cost benefit of treatment and prevention. We identified eight cost-of-illness studies, 15 analyses comparing the costs of different treatment options and 15 economic evaluations of prevention that m...

journal_title：PharmacoEconomics

authors： De Graeve D,Beutels P

更新日期：2004-01-01 00:00:00